• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Marillyn Hewson Joins Chevron’s Board of Directors

    12/2/20 4:30:00 PM ET
    $JNJ
    $CVX
    $LMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Integrated oil Companies
    Energy
    Get the next $JNJ alert in real time by email

    SAN RAMON, Calif.--(BUSINESS WIRE)--Chevron Corporation (NYSE: CVX) announced that Marillyn A. Hewson has been elected to Chevron’s board of directors, effective on January 1, 2021. She will serve on the Audit Committee of the Board.

    Hewson, 66, is executive chairman of Lockheed Martin Corporation. She served as Lockheed Martin’s chairman, president and chief executive officer from January 2014 to June 2020 and held the positions of president and chief executive officer from January 2013 to December 2013.

    “It’s truly an honor to welcome Marillyn to Chevron’s board,” said Chevron Chairman and CEO Michael Wirth. “Marillyn is one of the world’s most accomplished business leaders. She brings valuable global business experience as well as decades of perspective on international commerce and geopolitics to our board, and will make our company better.”

    Hewson joined Lockheed Martin more than 35 years ago as an industrial engineer. During her career she has held leadership positions across the corporation. She currently serves on the board of directors of Johnson & Johnson, the Congressional Medal of Honor Foundation, the Board of Governors of the USO, and as chair of the Catalyst Board of Directors. Hewson has served on several U.S. government advisory bodies, including her current appointment to the American Workforce Policy Advisory Board. She earned her Bachelor of Science degree in business administration and her Master of Arts degree in economics from The University of Alabama and has completed executive development programs at Columbia Business School and Harvard Business School.

    Chevron Corporation is one of the world’s leading integrated energy companies. Through its subsidiaries that conduct business worldwide, the company is involved in virtually every facet of the energy industry. Chevron explores for, produces and transports crude oil and natural gas; refines, markets and distributes transportation fuels and lubricants; manufactures and sells petrochemicals and additives; generates power; and develops and deploys technologies that enhance business value in every aspect of the company’s operations. Chevron is based in San Ramon, Calif. More information about Chevron is available at www.chevron.com.

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $CVX
    $LMT

    CompanyDatePrice TargetRatingAnalyst
    Lockheed Martin Corporation
    $LMT
    8/28/2025Neutral → Overweight
    Alembic Global Advisors
    Chevron Corporation
    $CVX
    8/20/2025$155.00Hold
    Melius
    Chevron Corporation
    $CVX
    8/4/2025$174.00Overweight
    Morgan Stanley
    Chevron Corporation
    $CVX
    8/4/2025$150.00 → $155.00Hold
    TD Cowen
    Chevron Corporation
    $CVX
    7/31/2025$180.00Outperform
    Evercore ISI
    Johnson & Johnson
    $JNJ
    7/23/2025Hold → Buy
    Erste Group
    Lockheed Martin Corporation
    $LMT
    7/23/2025$440.00Buy → Hold
    Truist
    Lockheed Martin Corporation
    $LMT
    7/10/2025$480.00Buy → Hold
    TD Cowen
    More analyst ratings

    $JNJ
    $CVX
    $LMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lockheed Martin upgraded by Alembic Global Advisors

    Alembic Global Advisors upgraded Lockheed Martin from Neutral to Overweight

    8/28/25 9:34:03 AM ET
    $LMT
    Military/Government/Technical
    Industrials

    Melius initiated coverage on Chevron with a new price target

    Melius initiated coverage of Chevron with a rating of Hold and set a new price target of $155.00

    8/20/25 8:33:34 AM ET
    $CVX
    Integrated oil Companies
    Energy

    Morgan Stanley resumed coverage on Chevron with a new price target

    Morgan Stanley resumed coverage of Chevron with a rating of Overweight and set a new price target of $174.00

    8/4/25 8:20:17 AM ET
    $CVX
    Integrated oil Companies
    Energy

    $JNJ
    $CVX
    $LMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $CVX
    $LMT
    SEC Filings

    View All

    SEC Form 144 filed by Johnson & Johnson

    144 - JOHNSON & JOHNSON (0000200406) (Subject)

    9/4/25 2:37:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Lockheed Martin Corporation

    8-K - LOCKHEED MARTIN CORP (0000936468) (Filer)

    8/29/25 4:40:08 PM ET
    $LMT
    Military/Government/Technical
    Industrials

    SEC Form N-PX filed by Johnson & Johnson

    N-PX - JOHNSON & JOHNSON (0000200406) (Filer)

    8/26/25 4:27:56 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $CVX
    $LMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum

    Johnson & Johnson (NYSE:JNJ) will present at the Bernstein 2nd Annual Healthcare Forum on Wednesday, September 24th, 2025. Management will participate in a Fireside Chat at 1:10 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20250908878054/en/ Media contact: [email protected] Investor contact: [email protected]

    9/8/25 4:25:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer

    Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year RARITAN, N.J., Sept. 7, 2025 /PR Newswire/ – Johnson & Johnson (NYSE: JNJ) today announced The New England Journal of Medicine (NEJM) published results from the Phase 3 MARIPOSA study, which showed RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival (OS) improvement for patients with previously

    9/7/25 3:22:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $CVX
    $LMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, WWC. Innovative Medicine Taubert Jennifer L exercised 56,471 shares at a strike of $101.87 and sold $10,040,883 worth of shares (56,471 units at $177.81) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    9/5/25 6:00:47 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP and Controller Knowles Alana K exercised 3,978 shares at a strike of $88.20 and sold $636,480 worth of shares (3,978 units at $160.00) (SEC Form 4)

    4 - CHEVRON CORP (0000093410) (Issuer)

    9/3/25 6:29:30 PM ET
    $CVX
    Integrated oil Companies
    Energy

    SEC Form 4 filed by Director Warner Cynthia J

    4 - CHEVRON CORP (0000093410) (Issuer)

    9/3/25 6:00:47 PM ET
    $CVX
    Integrated oil Companies
    Energy

    $JNJ
    $CVX
    $LMT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $CVX
    $LMT
    Leadership Updates

    Live Leadership Updates

    View All

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    John B. Hess Joins Chevron's Board of Directors

    Chevron Corporation (NYSE:CVX) announced that John B. Hess has been appointed to Chevron's Board of Directors. Hess, 71, served as CEO of Hess Corporation from 1995 to 2025 and as Chairman from 1995 to 2013. He led the company through its strategic transformation from an integrated oil company into a focused global independent exploration and production company. "We are excited to welcome John Hess to Chevron's Board," said Mike Wirth, Chevron's Chairman and CEO. "John not only built a great company, he is a highly respected industry leader, and our Board will benefit from his global experience, relationships and expertise." "I am delighted to join Chevron's Board of Directors at such

    7/29/25 8:15:00 AM ET
    $CVX
    Integrated oil Companies
    Energy

    Block Set to Join S&P 500

    NEW YORK, July 18, 2025 /PRNewswire/ -- Block Inc. (NYSE:XYZ) will replace Hess Corp. (NYSE:HES) in the S&P 500 effective prior to the opening of trading on Wednesday, July 23. S&P 500 and S&P 100 constituent Chevron Corp. (NYSE: CVX) has acquired Hess Corp in a deal that closed today, July 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name  Action Company Name Ticker GICS Sector July 23, 2025 S&P 500 Addition Block XYZ Financials July 23, 2025 S&P 500 Deletion Hess HES Energy For more information about S&P Dow Jones Indices, please visit www.spdji.com.  ABOUT S&P DOW JONES INDICES S&P Dow Jones Indi

    7/18/25 6:02:00 PM ET
    $CVX
    $HES
    $SPGI
    Integrated oil Companies
    Energy
    Finance: Consumer Services
    Finance

    $JNJ
    $CVX
    $LMT
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o

    9/3/25 4:29:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chevron Reports Second Quarter 2025 Results

    Reported earnings of $2.5 billion; adjusted earnings of $3.1 billion Record production; 1 million BOE per day in the Permian Basin Returned $5.5 billion cash to shareholders; 13 straight quarters of over $5 billion Completed acquisition of Hess Corporation in July Chevron Corporation (NYSE:CVX) reported earnings of $2.5 billion ($1.45 per share - diluted) for second quarter 2025, compared with $4.4 billion ($2.43 per share - diluted) in second quarter 2024. Included in the quarter was a net loss of $215 million related to the fair value measurement of Hess Corporation shares, and company pension curtailment costs, partly offset by a gain on the sale of certain non-operated U.S.

    8/1/25 6:15:00 AM ET
    $CVX
    Integrated oil Companies
    Energy

    Lockheed Martin Reports Second Quarter 2025 Financial Results

    Sales of $18.2 billionRecorded pre-tax losses on programs of $1.6 billion and other charges of $169 million, which impacted earnings per share by $5.83Net earnings of $342 million, or $1.46 per share, including impacts of program losses and other chargesCash from operations of $201 million and free cash flow of $(150) millionReturned $1.3 billion of cash to shareholders through dividends and share repurchasesReaffirming 2025 guidance for sales and free cash flowBETHESDA, Md., July 22, 2025 /PRNewswire/ -- Lockheed Martin Corporation (NYSE:LMT) today reported second quarter 2025 sales of $18.2 billion, compared to $18.1 billion in the second quarter of 2024. Net earnings in the second quarter

    7/22/25 7:29:00 AM ET
    $LMT
    Military/Government/Technical
    Industrials

    $JNJ
    $CVX
    $LMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Chevron Corporation (Amendment)

    SC 13G/A - CHEVRON CORP (0000093410) (Subject)

    2/13/24 4:55:53 PM ET
    $CVX
    Integrated oil Companies
    Energy